ID JOS-journal.pone.0163583
著者：名前 著者：別形式 Akimoto, Hayato / Oshima, Shinji / Negishi, Akio / Ohara, Kousuke / Ohshima, Shigeru / Inoue, Naoko / Kobayashi, Daisuke
著者：カナ 著者：所属 城西大学薬学部 / 城西大学薬学部 / 城西大学薬学部 / 城西国際大学薬学部 / 城西大学薬学部 / 城西大学薬学部 / 城西大学薬学部
著者：所属(別形式） Josai University, Faculty of Pharmaceutical Sciences / Josai University, Faculty of Pharmaceutical Sciences / Josai University, Faculty of Pharmaceutical Sciences / Josai International University, Faculty of Pharmaceutical Sciences / Josai University, Faculty of Pharmaceutical Sciences / Josai University, Faculty of Pharmaceutical Sciences / Josai University, Faculty of Pharmaceutical Sciences
著者版フラグ publisher
出版者 Public Library of Science (PLOS)
電子ISSN 19326203
掲載誌名 巻 11
号 9
刊行年月 2016-09-22
コンテンツ作成日 2016-01-16
コンテンツ修正日 2016-09-12
コンテンツ登録日 2016-09-22
識別番号：DOI info:doi/10.1371/journal.pone.0163583
識別番号：DOI（リンク） 抄録 Smoking Cessation Treatment (SCT) is a policy that has to be promoted for health economics, and expectations for the success of treatments with varenicline (VAR) are large. However, the Food and Drug Administration (FDA) have issued a warning on VAR-induced depression and suicide. In the present study, utilizing the FDA Adverse Event Reporting System (FAERS), we searched for antidepressants (ADs) used during SCT that cause fewer suicide-related events (SRE) (Study 1). We also investigated whether VAR concomitantly administered with ADs increases the risk of SRE (Study 2). In addition, we investigated whether the use of VAR alone is a latent risk factor of SRE. The backgrounds of cases with and without SRE were matched using the Propensity Score. In Study 1, the highest integrated Reporting Odds Ratio (iROR) was noted in concomitantly administered mirtazapine (iROR 6.98; 95% Confidence Interval (CI) 1.57–30.99), while the lowest ratio was noted in concomitantly administered amitriptyline (iROR 0.59; iROR95%CI 0.23–1.50). Study 2 clarified that SCT increases the risk of SRE in AD-treated cases (iROR 8.02; iROR95%CI 5.47–11.76; not significance). Of ADs concomitantly used during SCT with VAR, amitriptyline and mirtazapine showed the lowest and highest risks, respectively (Study 1). It was clarified that concomitant use of VAR in the treatment of depression with ADs increased the risk of SRE (Study 2). The results of Studies 1 and 2 suggested that the use of VAR alone is a latent risk factor inducing suicide.
キーワード 注記 Article number e0163583
言語 eng
資源タイプ text
ジャンル フォーマット application/pdf
権利 Copyright: c 2016 Akimoto et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
このアイテムを表示する：本文(pdf) ( 1.0MB) ダウンロード回数：
回
このアイテムを表示する：URI 
